Core Points - The company announced that all conditions precedent under Share Purchase Agreement I and Share Purchase Agreement II have been fulfilled, and the agreements were completed on October 2, 2025 [1] - A total of 2.753 billion shares were issued as consideration shares [1] - The company received a conversion notice from bondholders to fully exercise their conversion rights under the convertible bond, converting HKD 1.086 billion principal amount into 5.173 billion conversion shares at a conversion price of HKD 0.21 per share [1] - After completing the necessary administrative procedures for the issuance of conversion shares, the company issued 5.173 billion conversion shares to bondholders on October 2, 2025, which rank equally with all other existing shares [1]
大成生化科技完成根据特别授权发行代价股份及转换可换股债券